KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Long-Term Investments: 2022-2024

Historic Long-Term Investments for Xenon Pharmaceuticals (XENE) over the last 3 years, with Dec 2024 value amounting to $127.5 million.

  • Xenon Pharmaceuticals' Long-Term Investments fell 37.72% to $93.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.0 million, marking a year-over-year decrease of 37.72%. This contributed to the annual value of $127.5 million for FY2024, which is 56.46% down from last year.
  • As of FY2024, Xenon Pharmaceuticals' Long-Term Investments stood at $127.5 million, which was down 56.46% from $292.8 million recorded in FY2023.
  • Xenon Pharmaceuticals' 5-year Long-Term Investments high stood at $292.8 million for FY2023, and its period low was $127.5 million during FY2024.
  • Moreover, its 3-year median value for Long-Term Investments was $128.7 million (2022), whereas its average is $183.0 million.
  • In the last 5 years, Xenon Pharmaceuticals' Long-Term Investments spiked by 127.53% in 2023 and then slumped by 56.46% in 2024.
  • Over the past 3 years, Xenon Pharmaceuticals' Long-Term Investments (Yearly) stood at $128.7 million in 2022, then skyrocketed by 127.53% to $292.8 million in 2023, then tumbled by 56.46% to $127.5 million in 2024.